ESPERION®

Q2 2025 Earnings Presentation

August 5, 2025

Forward-looking Statements & Disclosures

This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this investor presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this investor presentation speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this investor presentation, other than to the extent required by law.

CEO Commentary

*"Our second quarter performance highlights the **strength** of our **commercial execution**, growing **adoption** of our **therapies**, and continued progress in **protecting** and **expanding** the long-term value of our portfolio. Our first quarter of **operating income** from ongoing business marks a key milestone towards achieving **sustainable profitability in Q1 2026**."*

Sheldon Koenig

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Q2 2025: Delivering Strong Momentum

Q2 TOTAL REVENUE

$82.4M

+12% growth

Q2 U.S. NET PRODUCT SALES

$40.3M

+42% growth

+10%

Retail Prescription Equivalents Q/Q

First Quarter of Operating Income from Ongoing Business

>28,000

Healthcare Providers Writing Scripts

ESPERION

Expanded Core Marketing Efforts to Reach Statin-Intolerant Patients





Can't take a statin? Make NEXLIZET happen!

- **Over 650,000** visits to our consumer statin intolerance website in Q2
- **More than 600,000** click throughs to our HCP statin intolerance site in Q2

Strong engagement underscores the impact of this successful, targeted awareness campaign

ESPERION

Strengthening Access and Driving Growth

Expanded payer coverage and reduced prior authorization requirements

Enhanced reimbursement support resources for patients and providers

Balanced direct and digital marketing approach

Resulted in:

- **10% increase** in total retail prescription equivalents vs. Q1 2025
- Now over **28,000** total HCPs
- **23%** of prescriptions written by physicians with only digital touchpoints
- **38%** of new writer prescriptions were driven by digital only touchpoints
- **Approval rates of more than 80%** following education of 1,100+ target prescribers by our expanded U.S. fields reimbursement team

Reflects growing clinical confidence and broader adoption among statin intolerant patients

Award-Winning Consumer Campaign: Lipid Lurkers

- **Tackling the silent threat of high cholesterol** through a bold, creative lens
- Introduces **Lipid Lurkers** – mischievous characters that personify the hidden dangers of LDL-C
- **Educates and empowers** patients to take the next steps after statins
- Drives awareness for **NEXLETOL**® (bempedoic acid) and **NEXLIZET**® (bempedoic acid and ezetimibe)

Winner of the prestigious Med Ad News Award for "Best Consumer Digital Campaign"

Finalist for multiple additional awards in 2025

Advancing Growth Through Strategic Execution

Consumer Awareness Expansion

- Launch consumer television ad on connected TV (e.g., Hulu, NBC Sports) later this year
- Ad will feature our award-winning Lipid Lurkers and aim to raise awareness of statin intolerance

Growth Drivers and Strategic Outlook

- Continued momentum supported by our marketing and sales initiatives and improving payer dynamics
- Advancing development of triple combination products
- Actively evaluating in-licensing and acquisition opportunities to leverage our commercial infrastructure

IP Protection and Legal Progress

- Reached settlements with three ANDA filers not to market generic versions of NEXLETOL prior to 2040
- Ongoing efforts to further strengthen our IP position

Pipeline Expansion: Novel ACLY Biology

- Advancing IND-enabling studies for new program in primary sclerosing cholangitis (PSC)
- PSC: rare, progressive liver disease with no approved therapies
- Represents ~1B annual market opportunity
- On track to file IND and potentially begin first-in-human studies in 2H 2026

Strategic Partnerships Driving Global Reach

Approved in **40** countries globally

Maximizing Global Reach Across Key Regions

	Europe	Japan	Asia & South America	Israel	Australia & New Zealand	Canada
Partner	Daiichi Sankyo Europe	Otsuka Pharmaceutical Co., Ltd.	Daiichi Sankyo Co., Ltd.	Neopharm Israel	CSL Seqirus	HLS Therapeutics
Agreement Terms	Tiered royalties and additional sales milestones	Tiered royalties, regulatory, pricing and additional sales milestones	Tiered royalties and additional sales milestones	Tiered royalties and additional milestones	Upfront and near-term milestone payments	Upfront Payment, Milestones and Tiered Royalties

Highlights	• Launched in many key markets including Germany, UK, Austria, Belgium, Switzerland, Italy, Spain, Netherlands, Slovakia and Czech Republic to date
	• Expanded label approved in EU and UK in May/June '24
		• Expect approval and National Health Insurance pricing in the second half of 2025	• Received regulatory approval to market product (mono & dual) and launched:
			  • Hong Kong in 2023
			  • Thailand and Macau in 2024
			• Received regulatory approval to market product (mono)
			  • Myanmar and Taiwan in 2024
				• Filed NDA for marketing approval in Q1 2025; approval anticipated in the first half of 2026	• Filed marketing application in Australia in July 2025
					• Expect market approval in Q4 2026
						• Expect market approval in Q4 2025

Approval and launch in additional territories anticipated in 2025

International Growth Continues at Strong Pace



~555,000
patients through May'25

Note: Numbers are approximate and based on an internal calculation methodology and includes Germany, UK, Austria, Belgium, Switzerland, Italy, Spain, the Netherlands.

ESPERION®

Pipeline Advancement

Proven Science, Innovative Pipeline

Innovative Portfolio & Pipeline

PRODUCT/PROGRAM	EXPLORATORY	LEAD ID	LEAD OPTIMIZATION	PRECLINICAL DEVELOPMENT	CLINICAL DEVELOPMENT	APPROVED / COMMERCIAL	MILESTONES
Cardiovascular Disease (LDL-C lowering / CV Risk reduction)							
NEXLETOL® bempedoic acid							Approved 2020 Expanded label 2024
NEXLIZET® bempedoic acid and ezetimibe							Approved 2020 Expanded label 2024
Triple Combination A bempedoic acid, ezetimibe, and atorvastatin							NDA: 2027
Triple Combination B bempedoic acid, ezetimibe, and rosuvastatin							NDA: 2027
Liver Diseases							
Primary Sclerosing Cholangitis (PSC)							IND: 2026
Renal Diseases							To Be Announced



LDL-C: low-density lipoprotein cholesterol; CV: cardiovascular; NDA: New Drug Application; IND: Investigational New Drug

ESPERION®

High Unmet Need Driving Significant Market Opportunity

PSC: A Rare and Progressive Liver Disease

>$1B Annual Market Opportunity Estimate

- **No approved therapies** with proven efficacy to cure or halt PSC progression
- Potential **Orphan Drug Designation & Fast Track** Approval
- Discovery program is **internally developed and wholly-owned globally**

This program highlights the broader potential of ACLY biology

PSC: primary sclerosing cholangitis

Financial Update

Ben Halladay, Chief Financial Officer

Exceptional Second Quarter Drives Path to Profitability

First Quarter of Operating Income from Ongoing Business in Company's History

Supports Transition to Sustainable Profitability Beginning in Q1 2026

TOTAL REVENUE

$82.4M

+12% increase

U.S. NET PRODUCT SALES

$40.3M

+42% increase

COLLABORATION REVENUE

$42.1M

-7% decrease

+105% increase

Adjusting for one time settlement agreement milestone with DSE received in Q2 2024

Cash and 2025 Guidance

Cash & Cash Equivalents

$86.1M

Key Financial Data

FY 2025 R&D Guidance	$55 – 65 M
FY 2025 SG&A Guidance	$160 – 170 M
FY 2025 OpEx Guidance[1]	$215 – 235 M

1. Includes ~$15 million of non-cash stock-based compensation expense

Strong Prescription Demand and Increasing Physician Adoption Continue to Drive Durable Revenue Growth





1. Through June 30, 2025.

ESPERION®

Important Safety Information

NEXLETOL® (bempedoic acid) Important Safety Information

- NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred.
- Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
- Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.
- The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.
- The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.
- Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLETOL.
- Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

See full prescribing information here.

NEXLIZET® (bempedoic acid and ezetimibe) Important Safety Information

- NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been reported with ezetimibe or bempedoic acid.
- Hyperuricemia: Bempedoic acid, a component of NEXLIZET, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
- Tendon Rupture: Bempedoic acid, a component of NEXLIZET, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.
- The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid (a component of NEXLIZET) in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.
- Adverse reactions reported in ≥2% of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza.
- In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence ≥3% and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were urinary tract infection, nasopharyngitis, and constipation.
- The most common adverse reactions in the cardiovascular outcomes trial of bempedoic acid (a component of NEXLIZET) at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.
- Discontinue NEXLIZET when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLIZET.
- Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

See full prescribing information here.